Medical Devices North America

North America Renal Denervation Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

North America Renal Denervation Market Industry Trends and Forecast to 2034: Segmented by (Technology, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $234.7 Mn Placeholder estimate
Estimate 2025 $290.6 Mn 46.5% of the global market
Projected 2034 $1.99 Bn 583.1% Adds $1.69 Bn over 9 forecast years
CAGR 2025–2034 23.8% Faster than 97% of 180 Medical Devices markets here
Key players 5
  • North America is 46.49% of the global market.
  • Among regions, the largest is North America (this report) at $290.6 Mn.
  • Fastest growing: Latin America at 26.2% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.69 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Renal Denervation Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $234.7 Mn — —
2025 (base) $290.6 Mn +$55.9 Mn —
2026 (forecast) $359.7 Mn +$69.2 Mn +23.8%
2027 (forecast) $445.4 Mn +$85.6 Mn +53.3%
2028 (forecast) $551.4 Mn +$106.0 Mn +89.7%
2029 (forecast) $682.6 Mn +$131.2 Mn +134.9%
2030 (forecast) $845.1 Mn +$162.5 Mn +190.8%
2031 (forecast) $1.05 Bn +$201.1 Mn +260%
2032 (forecast) $1.30 Bn +$249.0 Mn +345.7%
2033 (forecast) $1.60 Bn +$308.2 Mn +451.8%
2034 (forecast) $1.99 Bn +$381.6 Mn +583.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

North America Renal Denervation Market Analysis at a glance
Market size, 2025$290.6 Mn placeholder estimate
Forecast, 2034$1.99 Bn placeholder estimate
Growth (CAGR), 2025–203423.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, product and end user (see all)
Key playersMedtronic, Recor Medical (Otsuka), Boston Scientific Corporation, SoniVie, Ablative Solutions (see all)
Active clinical trials14 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Renal Denervation Market Analysis Executive Summary

Renal denervation uses energy delivered through a catheter to calm nerves near the kidneys and lower hard-to-control high blood pressure.

Key segments of the renal Denervation market include technology (Radiofrequency, Ultrasound and Chemical) and product (Catheters and Generators).

Bar chart: North America Renal Denervation market size, 2024–2034, placeholder estimates. $234.7 Mn in 2024, $290.6 Mn in 2025 and $1.99 Bn in 2034, 23.8% CAGR.
North America Renal Denervation market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Renal Denervation Market Dynamics

Market Growth Drivers

Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.

Opportunity

Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the renal Denervation market room to grow.

Market Restraints

High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the renal Denervation market.

Competitive Landscape for Renal Denervation Market in North America

The renal Denervation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Renal Denervation Market in North America

Renal Denervation in North America: rules, payment and research

In the countries we cover here, medical devices are regulated by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4]. ClinicalTrials.gov lists 14 studies on Renal Denervation that are recruiting, active or about to start in North America.⁠[5]

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[5] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how renal Denervation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Renal Denervation right now, from free public sources.

Clinical trials

14 active trials in US and Canada

Recruiting, about to start, or running now. Counted across the 2 countries we report on in North America.

Top trial sponsors (worldwide)

  1. Medtronic 6 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanghai Golden Leaf MedTec Co. Ltd 2 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Ablative Solutions 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. SyMap Medical (Suzhou), Ltd. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Recor Medical (Otsuka) 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 985 papers since 2021 (worldwide)

  1. Extravascular Renal Denervation for Resistant Hypertension: First-in-Human Study. Hypertension (Dallas, Tex. : 1979), 2026
  2. Sympathovagal Imbalance and Insulin Resistance: The Autonomic Nervous System as a Convergent Therapeutic Target for Breaking a Bidirectional Pathogenic Cycle. Diabetes, metabolic syndrome and obesity : targets and therapy, 2026
  3. Improved time in therapeutic range and reduced medication burden after renal denervation: a nationwide real-world registry. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
  4. Computed tomography-derived optimal fluoroscopic projections to guide renal denervation. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
  5. Blood pressure response to methyldopa as a potential indicator of renal denervation responsiveness in resistant hypertension: a case report. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Renal Denervation in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Renal Denervation market in North America?
Placeholder estimate: about $290.6 Mn in 2025, rising to about $1.99 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Renal Denervation market in North America growing?
Placeholder estimate: about 23.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Renal Denervation market report cover?
The report splits the market by technology (Radiofrequency, Ultrasound, Chemical), product (Catheters, Generators) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Renal Denervation market?
Key players include Medtronic, Recor Medical (Otsuka), Boston Scientific Corporation, SoniVie and Ablative Solutions.
What is driving the Renal Denervation market?
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.
How many clinical trials on Renal Denervation are running in North America?
14 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on Renal Denervation?
PubMed lists 985 papers on Renal Denervation added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in North America

See all

Related on hypertension and cardiovascular

See the topic